Generic Name and Formulations:
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%; foam.
LEO Pharma Inc.
Indications for ENSTILAR:
Apply to affected areas once daily for up to 4 weeks; discontinue when control is achieved. ≥18yrs: max 60g every 4 days. Do not occlude.
<18yrs: not studied.
Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, or irritation occurs. Do not use on face, axillae, or groin, or if atrophy is present at treatment site. Avoid eyes, sun, UV light (eg, phototherapy). Flammable. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Vit. D3 derivative + topical steroid.
Systemic absorption potentiated by other corticosteroids.
Application site irritation and pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, psoriasis exacerbation.
Foam (60g)—1, 2
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age